Chemotherapy-induced nausea and vomiting (CINV) is common during cancer treatment due to a complex multifactorial process involving several different pathways and transmitters. Highly emetogenic chemotherapy (HEC) regimens are associated with >90% risk of emesis if no antiemetics are provided.
Ten-Year Trends in Antiemetic Prescribing in Patients Receiving Highly Emetogenic Chemotherapy
, and olanzapine) have occurred over the past 2 decades. 5 FDA approval of 5-HT3RAs in the late 1990s was an important step toward improved control of CINV. Ondansetron and granisetron are first-generation 5-HT3RAs, and palonosetron is a second-generation 5-HT3RA that has a significantly longer half-life than the first-generation compounds. The combination of palonosetron and glucocorticoids has resulted in superior control of delayed emesis compared with glucocorticoids combined with first-generation 5-HT3RAs. 6, 7 The subsequent approval of the NK1RAs (initially oral aprepitant [2003] ) was another landmark advance in antiemetic prophylaxis. Aprepitant was shown to consistently prevent CINV across a broad range of chemotherapy regimens. 8, 9 Fosaprepitant is a water-soluble derivative of aprepitant and is rapidly converted to aprepitant after intravenous administration. A large randomized noninferiority trial demonstrated that a single dose of intravenous fosaprepitant on day 1 of chemotherapy was comparable in efficacy to the standard 3-day oral aprepitant regimen. 10 The more convenient intravenous dosing schedule was offered as a way to assure medication compliance.
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In the recent past, several groups reported that fosaprepitant caused substantial venous irritation, especially with doxorubicin-based chemotherapy regimens that were administered by peripheral venous access. [12] [13] [14] [15] For example, venous toxicity was observed in 35% of patients receiving intravenous fosaprepitant followed by doxorubicin/cyclophosphamide (AC) compared with only 2% of patients receiving oral aprepitant with AC. 16 In a separate retrospective study, only 7% of patients receiving fosaprepitant with nonanthracycline platinum-based chemotherapy regimens experienced venous toxicity. 13 A variety of antiemetic guidelines are available from NCCN, ASCO, ESMO, and the Multinational Association of Supportive Care in Cancer (MASCC). [17] [18] [19] The current consensus is that a combination of dexamethasone, a 5-HT3RA (eg, ondansetron, granisetron, dolasetron, or palonosetron), and an NK1RA (eg, aprepitant, fosaprepitant, netupitant, or rolapitant) is an appropriate preventative regimen in patients receiving HEC. However, considerable debate remains regarding how long patients should receive dexamethasone after chemotherapy. 20 Recent NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Antiemesis suggest that olanzapine be considered either in place of or in addition to the NK1RA in patients receiving HEC. 19 Extensive literature exists on the use of antiemetics in patients with cancer. For example, a PubMed search using the terms "antiemetics" and "cancer" identified 16,392 potentially relevant articles. Further, there are multiple options in the ASCO and ESMO/MASCC guidelines pertaining to the use of 5-HT3RAs and NK1RAs, 1, 18 which vary in modes of administration (oral, intravenous, or transdermal) and cost. The current NCCN Guidelines for Antiemesis illustrate the 42 different "guideline-approved" options for the prevention of acute and delayed emesis in patients with cancer receiving HEC (available at NCCN.org [page AE-5]). 19 These include various combinations of several different agents, schedules, and modes of administration.
The current study was developed to address a number of questions regarding the use of antiemetics in the real clinical-practice world, including how often dexamethasone is really used in patients receiving HEC, which of the 5HT3RAs and NK1RAs have been used over time, and whether published data regarding vein toxicity from fosaprepitant change the its use, particularly in patients who received peripheral vein drug administration. Additionally, given pilot nonrandomized data dating back to 2004 21, 22 and pilot randomized controlled data from 2011 supporting that olanzapine was helpful for decreasing CINV, 23 we also sought to determine whether olanzapine use increased in clinical practice before the 2016 publication of results of a doubleblind, randomized, placebo-controlled clinical trial.
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Methods
Data Source
We performed a retrospective study using the OptumLabs Data Warehouse, which includes administrative claims data for >100 million privately insured and Medicare Advantage enrollees in the United States over the past 20 years. 25 The database contains longitudinal health information from geographically diverse regions across the United States, with greatest representation from the South and Midwest. 26 The included health plans provide data covering several domains, including enrollee information (insurance plan, sex, age, race/ethnicity, region of residence, dates of eligibility), outpatient pharmacy claims (prescribing physician, fill dates, days of supply, strength), professional claims (eg, visits to physicians' offices), and facility claims (eg, hospitalizations). 26 This study analyzed preexisting, deidentified data, and was therefore deemed exempt from Institutional Review Board approval.
Study Population
We identified patients who initiated AC, TAC (paclitaxel or docetaxel with doxorubicin and cyclophosphamide), or cisplatin between January 2006 and March 2016. Subsequent cisplatin doses had to be at least 14 days later than the first dose to reduce the likelihood that patients receiving low-dose weekly (less emetogenic) cisplatin were included in the analysis. Patients were required to have at least 30 days of medical and pharmacy insurance coverage prior to and after initial chemotherapy treatment. Antiemetic use was determined by identifying intravenous/oral/transdermal administration within ±1 day of index chemotherapy and/or prescription fill within 14 days prior to and 7 days after index chemotherapy. Antiemetic medications evaluated included dexamethasone, ondansetron, granisetron, palonosetron, aprepitant, fosaprepitant, netupitant, rolapitant, and olanzapine.
Statistical Analysis
Patient characteristics (age, sex, race, region) were described using mean (SD) or frequencies (percentage) as appropriate. The proportion of patients initiating AC, TAC, or cisplatin chemotherapy regimens (denominator) and taking an antiemetic medication (numerator) in each quarter of the study period was calculated. Trends of antiemetic use were presented overall and separately for 5HT3RAs and NK1RAs. Statistical analysis using SAS 9.4 (SAS Institute Inc., Cary, NC) was used to evaluate trends in antiemetic use over time.
Results
We identified 34,236 patients who received AC, TAC, or cisplatin from the first quarter of 2006 (Q1) to the second quarter (Q2) of 2016 ( Figure 1 ). Patient demographics are shown in Table 1 . Figure 2 shows overall trends in antiemetic prescribing from 2006 through 2016. Predictably, nearly all patients who received HEC were given antiemetics. Dexamethasone use was most common and consistent over time, identified in 85% to 90% of patients consistently over the entire study period. Figure 4 illustrates that aprepitant, which was the only NK1RA clinically available prior to 2008, was used in 40% to 50% of patients around that time, but then its use decreased sharply between 2010 and 2011, declining to <5% in 2016. This decline in aprepitant use coincided with a dramatic increase in the use of fosaprepitant after it became available in 2008. In addition to fosaprepitant replacing the use of aprepitant, its availability appeared to increase the use of an NK1RA for HEC from approximately 49% to approximately 80%. No evidence suggested that the underuse of NK1RA (vs dexamethasone and 5HT3RA) resulted from physicians believing that they did not need it when they used the more effective 5HT3RA (palonosetron), because the use of an NK1RA was slightly more likely (nonsignificantly) in patients who received palonosetron compared with another 5HT3RA.
Trends in NK1RA Use
Notably, no decrease in use of fosaprepitant was observed after initial reports in 2014 that it may cause venous toxicity. Understanding that the intravenous toxicity of fosaprepitant only seemed to occur in patients with peripheral vein administration, the use of aprepitant and fosaprepitant were evaluated in patients with only peripheral vein access, excluding those with central vein access. These data similarly revealed that there was not any apparent decrease in fosaprepitant use after 2014 in patients with only peripheral vein access. During the dates assessed in the current project, uptake of netupitant/palonosetron and rolapitant was low, with only minimal use in 2015-2016 ( Figure 2B ).
Olanzapine Use
Use of olanzapine was minimal over time, but started to slowly increase in the third quarter of 2015 (Figure 2 ).
Subsets of Subjects Receiving Different Chemotherapy Regimens
Trends in antiemetic use in patients who received AC, TAC, or cisplatin were similar to those observed in the overall study population.
Discussion
Recent reports suggest that existing antiemetic guidelines are not well followed, 27, 28 with compliance rates of approximately 50% to 60%. 29 Factors that have been shown to negatively impact guideline adherence include (1) the complexity of prophylactic treatment for HEC, (2) mucositis, (3) depression, (4) polypharmacy, (5) physician workload, and (6) suboptimal communication between provider and patient. 27, [29] [30] [31] In one trial, the use of computerized physician order entry for antiemetics resulted in a 97% rate of compliance with guidelines. 32 Results from our study shed some light on several issues regarding the clinical use of antiemetics in patients receiving HEC in the United States.
First, our data show that antiemetic agents, including dexamethasone, were used in virtually all patients, which shows that our methodology captured real practice use of these drugs. The frequent use of dexamethasone (in 85%-90% of patients) suggests that clinicians agree with guideline recommendations that steroids should be given routinely to patients receiving HEC. It is likely that comorbid conditions (eg, poorly controlled diabetes) led to the omission of this drug in some patients, such that it should not be expected that 100% would receive it. The virtually universal receipt of 5HT3RAs in this population is also consistent with guideline recommendations. It is clear from the presented data that palonosetron is a favorite. Other data supporting the common use of palonosetron for HEC in clinical practice come from a recent randomized trial 24 that accrued patients between August 2014 and March 2015, which evaluated olanzapine versus placebo in conjunction with dexamethasone, a 5HT3RA, and an NK1RA. In this study, clinicians were able to choose which 5HT3RA they used; 76% chose palonosetron, 24% chose ondansetron, and <1% chose granisetron. It is worth noting that palonosetron is much more expensive than other 5HT3RAs, and that current guidelines support the use of a less expensive 5HT3RA when an NK1RA is also being used. Dolasetron use was infrequent throughout, but became substantially more infrequent after 2010. This may have been related to an FDA safety alert in December 2010 regarding a risk of torsades de pointes. 33 The observation that the total use of one or more 5HT3RAs exceeded 100%, illustrated in Figure 3 , may reflect the fact that patients receiving palonosetron were also given ondansetron scripts to fill in case they experienced nausea or vomiting. However, it could be argued that giving another 5HT3RA to someone who has nausea/vomiting following palonosetron might not be the best approach. Another agent, such as olanzapine 34 or prochloperazine, 35 might be a better choice in this situation. With regard to the use of NK1RAs, the dramatic replacement of aprepitant by fosaprepitant may be due to the more convenient intravenous administration of this NK1RTA, as well as reimbursement issues. It is not clear why, despite the 2014-2015 publications of venous toxicity in a number of patients receiving intravenous fosaprepitant through a peripheral intravenous line, 12, 13 there did not appear to be evidence of a subsequent trend away from fosaprepitant and toward aprepitant. As opposed to the almost universal use of guideline-recommended dexamethasone and 5HT3RA use in patients receiving HEC in this study, it is interesting to note that this is not true with the NK1RAs, for which use only recently approached 80%, and in 2011 was only 60%. The NCCN Guidelines for Antiemesis first recommended use of NK1RAs in 2004, and the ASCO guidelines followed suit in 2006.
It is too early to ascertain how the use of the 2 newer NK1RAs, rolapitant and netupitant (presently only available as a combination oral product that also includes palonosetron), will change over time, and whether these new drugs will offer enough of an advantage over fosaprepitant in terms of efficacy, toxicity, and/or cost.
Lastly, the data from this study show that olanzapine was not commonly received, despite the pilot data suggesting its efficacy. 21, 22, 24 It will be interesting to see whether it will be used more frequently over the next several years now that antiemetic guidelines include this drug, and the results from a large placebo-controlled, double-blinded clinical trial support its efficacy when combined with an NK1RA, a 5HT3RA, and dexamethasone.
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Limitations
The biggest weakness of our study is that it is not clear whether each antiemetic drug was administered as a means of trying to prevent CINV or as a treatment of established CINV. Other limitations include the inability to compare antiemetic use between the academic and community settings, and the lack of regional information. Further, we did not have information regarding doses or costs of the antiemetics used, and it was not possible to be certain whether olanzapine was prescribed for a psychiatric indication or for nausea prophylaxis. Given the limitations of the study design, causation cannot be inferred.
Conclusions
Our findings showed that dexamethasone and 5HT3RAs were used in most patients receiving HEC, in accordance with guideline recommendations. Less compliance with guidelines was seen with NK1RA use.
